RBR-3wshg2m
Recruiting
Phase 4
Analysis of humoral and cellular immune responses to 13-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine in patients living with HIV/AIDS
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo0 sitesJune 29, 2023
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •HIV\-infected patients confirmed by confirmatory tests (Western\-Blott and/or HIV polymerase chain reaction viral load) who are of any gender identity. Being in regular use of highly effective antiretroviral, according to the definitions of the Ministry of Health, for at least four weeks. Minimum age 18 years old. Signature of the Free and Informed Consent Form (Appendix A) . For the control group: negative quick test for HIV
Exclusion Criteria
- •Patient with a history of anaphylactic reaction to pneumococcal conjugate vaccines (PCV\-7, PCV\-10 or PCV\-13\) or 23\-valent pneumococcal polysaccharide vacines. Previous vaccination with PCV\-7, PCV\-10, PCV\-13 (interference in the evaluation of the pre\-vaccination humoral immune response). Have been vaccinated with PPV\-23 less than 1 year ago. Transfusion of blood components or Immunoglobulins in the last 28 days before vaccination with PCV\-13 or PPV\-23\. Blood dyscrasias that prevent intramuscular vaccine application; Fever in the last 24 hours before vaccination
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Study to the humoral and cellular immuneresponse after influenzavaccination in patients with metastasized RCC or GIST treated with a tyrosine kinase inhibitor(sunitinib or sorafenib)GISTkidney cancer10038363NL-OMON32710niversitair Medisch Centrum Sint Radboud75
Completed
Not Applicable
Investigation of the humoral and cellular immunity against SARS-CoV2 in patients after kidney transplantation in pandemic timesU07.1COVID-19, virus identifiedDRKS00024171niversitätsklinikum Köln46
Active, not recruiting
Not Applicable
A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac) - mgus-vacc responsEUCTR2010-022693-14-NLuniversity medical centre groningen
Completed
Not Applicable
A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac)MGUSMonoclonal gammopathy of undetermined significance10035227NL-OMON34204niversitair Medisch Centrum Groningen122
Active, not recruiting
Not Applicable
Characterisation of humoral and cellular immunity of low- and high-responder after TBE vaccinatioEUCTR2008-005800-24-ATMedizinische Universität Wien, Institut für Spezifische Prophylaxe und Tropenmedizin84